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ABSTRACT
Noroviruses are the leading cause of acute gastroenteritis outbreaks worldwide. The majority of norovirus outbreaks are caused
by genogroup II.4 (GII.4). Novel GII.4 strains emerge every 2 to 4 years and replace older variants as the dominant norovirus.
Novel variants emerge through a combination of recombination, genetic drift, and selection driven by population immunity, but
the exact mechanism of how or where is not known. We detected two previously unknown novel GII.4 variants, termed GII.4
UNK1 and GII.4 UNK2, and a diverse norovirus population in fecal specimens from immunocompromised individuals with di-
arrhea after they had undergone bone marrow transplantation. We hypothesized that immunocompromised individuals can
serve as reservoirs for novel norovirus variants. To test our hypothesis, metagenomic analysis of viral RNA populations was
combined with a full-genome bioinformatic analysis of publicly available GII.4 norovirus sequences from 1974 to 2014 to iden-
tify converging sites. Variable sites were proportionally more likely to be within two amino acids (P < 0.05) of positively selected
sites. Further analysis using a hypergeometric distribution indicated that polymorphic site distribution was random and its
proximity to positively selected sites was dependent on the size of the norovirus genome and the number of positively selected
sites.In conclusion, random mutations may have a positive impact on driving norovirus evolution, and immunocompromised
individuals could serve as potential reservoirs for novel GII.4 strains.
IMPORTANCE
Norovirus is the most common cause of viral gastroenteritis in the United States. Every 2 to 3 years novel norovirus variants emerge
and replace dominant strains. The continual emergence of novel noroviruses is believed to be caused by a combination of genetic drift,
population immunity, and recombination, but exactly how this emergence occurs remains unknown. In this study, we identified two
novel GII.4 variants in immunocompromised bone marrow transplant patients. Using metagenomic and bioinformatic analysis, we
showed that most genetic polymorphisms in the novel variants occur near 0 to 2 amino acids of positively selected sites, but the distri-
bution of mutations was random; clustering of polymorphisms with positively selected sites was a result of genome size and number of
mutations and positively selected sites. This study shows that immunocompromised patients can harbor infectious novel norovirus
variants, and although mutations in viruses are random, they can have a positive effect on viral evolution.
Noroviruses are the leading cause of gastroenteritis outbreaksworldwide (1, 2), causing approximately 50% of all such out-
breaks. Noroviruses are the primary cause of community and
outpatient visits for acute gastrointestinal disease (AGE) (3). Al-
though for most people the disease is relatively mild and self-
limiting, morbidity and mortality due to norovirus infection are a
concern for young children, immunocompromised individuals,
and the elderly (4–6). In the elderly population, noroviruses have
been shown to have mortality rates (5, 7) second only to that of
Clostridium difficile (8).
Norovirus can be classified into seven genogroups (G), of
which viruses belonging to GI and GII are responsible for the
majority of human disease (9, 10). GII contains 22 recognized
genotypes (50), of which GII.4 is the most common, causing 69 to
72% of all norovirus outbreaks in North America (11, 12). The
genome of noroviruses is organized into three open reading
frames (ORF). ORF1 is translated as a polyprotein that is cleaved
by the virus-encoded protease into six nonstructural proteins.
ORF2 and ORF3 code for the major capsid protein (VP1) and the
minor capsid protein (VP2), respectively. VP1 forms the icosahe-
dral shell that is divided into two well-defined motifs, designated
the S (shell) and protruding (P) domains. The P domain is further
subdivided into the P1 and P2 subdomains. The surface-exposed
P2 subdomain contains the antigenic and histo-blood group an-
tigen (HBGA) binding sites and is characterized by a high muta-
tion frequency (13). The rate of evolution for GII.4 noroviruses
has been determined to be 4.3  103 nucleotide substitutions per
site per year in the major capsid protein (14, 15). Studies with
other viruses have identified a fine balance between fidelity and
viral fitness, where any increase or decrease of fidelity has a nega-
tive fitness effect on virus replication and pathogenesis (16–21).
For norovirus, aside from the VP1 region, there are few studies
identifying positively selected codon sites (14, 16, 22, 23). Thus,
the disease burdens associated with norovirus, which vary substan-
tially and temporally, are regulated in part by a poorly understood
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process of recombination, continual evolution, and emergence of
novel norovirus strains that circulate in human populations.
A growing number of reports have documented chronic noro-
virus shedding due to an immune disorder, HIV infection, or
other underlying conditions (24–30). Recent studies have also
shown that noroviruses are the most common pathogen in hospi-
talized children with an immunodeficiency and that the majority
of these children have prolonged virus shedding (31). Previous
studies involving immunocompromised individuals have identified a
large diversity of norovirus populations in these chronic shedders
(24–28), and over time antigenic changes occur (32). Norovirus met-
agenomic analyses of immunocompromised populations have been
attempted, but these involve sequencing site-specific PCR products
or using RNA virus population reconstruction software (33–35). Re-
constructing the norovirus genome is difficult due to the conserved
junction region in the ORF1/ORF2 region and the high error rates
associated with reconstruction software (35). A full-genome analysis
of norovirus RNA populations and how they relate to norovirus evo-
lution has not been accomplished.
In this study, we determined site-by-site variation in the RNA
population (a comparison of individual genomes that compose
the mutant spectrum of a sample, also referred to as quasispecies)
of four patients infected with norovirus. Two were immunosup-
pressed using a transplant drug regimen, one patient had com-
bined immunodeficiency disease, and the last patient was a
healthy elderly male. We analyzed the norovirus population from
1972 to 2014 using 541 full or near full-length genomes. Full-
genome analysis identified NS4 and VP1 as the most positively
selected genes in the norovirus genome, indicating an important
yet unknown function for the NS4 protein. We tested for conver-
gent sites between the immunocompromised and the circulating
populations to determine similar evolutionary trends. We hy-
pothesized that immunocompromised individuals infected with
noroviruses are able to serve as reservoirs for novel GII.4 norovi-
ruses by preferentially mutating around norovirus genome posi-
tively selected sites. We found that mutations occur dispropor-
tionally within 2 and 4 amino acids (aa) of positively selected sites.
When genome size, number of selective sites, and available sites
were taken into account, the location of mutations was not signif-
icant, indicating a random distribution of mutations. These re-
sults provide new insight into norovirus evolution.
MATERIALS AND METHODS
Patient information and specimens. A total of five stool specimens from
four bone marrow transplant recipients were collected as part of an out-
break investigation (Table 1). Patients exhibited chronic diarrhea and
were undergoing immunosuppressive drug therapy. Specimens from im-
munocompromised patients were collected within 1 day of each other
unless otherwise indicated. All specimens tested positive for GII norovirus
by real-time reverse transcription-PCR (RT-PCR) and typed as GII.4 by
sequence analysis of region D and P2 (36), nucleotides (nt) 6469 to 6622
and nt 5904 to 6338, of Lordsdale virus (GenBank accession number
X86557), respectively. The first three specimens were collected in April
2010 from different patients (A, B, and C) with acute gastroenteritis. The
fourth specimen (A  5) was collected from patient A 5 months after the
first sample. A GII.4 New Orleans-positive specimen collected from an
immunocompetent (IC) patient in a cruise ship outbreak in 2010 was
processed concurrently to determine process-induced or naturally occur-
ring polymorphisms (GenBank accession number JN595867).
Cloning and quantitation of norovirus genomes. The VP1 and par-
tial VP2 regions were amplified and cloned using previously described
methods (36). Briefly, RNA was extracted from 10% stool suspensions
using an automated KingFisher magnetic particle processor (Thermo
Fisher Scientific, Pittsburgh, PA). A 2.3-kbp fragment from VP1 and part
of VP2 were amplified using GII norovirus conserved primers Ring2-PCR
and panGIIR (37). Ten clones from each specimen, a total of 50, were
bidirectionally sequenced and analyzed (GenBank accession numbers
KF806495 to KF806534). Ten clones from the immunocompetent indi-
vidual were identical to the sequence with accession number JN595867.
Norovirus RNA copy number was determined by real-time RT-PCR as
previously described (38) using a purified and DNase-treated RNA tran-
script from a GII.7 outbreak (GenBank accession number GU134965).
Deep-sequencing sample preparation. Specimens were processed as
previously described (39). Briefly, clarified 10% stool suspensions were
prepared in phosphate-buffered saline (PBS). After clarification by low-
speed centrifugation, the supernatant was extracted three times with Ver-
trel XF and pooled supernatants were filtered through a 0.45-m filter
before centrifugation over a 30% sucrose cushion at 237,000  g for 2 h at
4°C. The virus pellet was resuspended in PBS and treated with DNase
Turbo, Benzonase, and RNase One for 2 h at 37°C. The RNA from intact







RNA copy no. Health information Drug regimen
IC GII.4 New Orleans 66 yrs Male 2.7  109 RNA
copies/ml
No known health complications None reported
A GII.4 UNK2 16 yrs Male 2.4  108 RNA
copies/ml
Combined immunodeficiency, bone






A  5 GII.4 UNK1, UNK2 17 yrs Male 3.2  106 RNA
copies/ml
Combined immunodeficiency, bone





B GII.4 UNK1 16 mo Female 3.3  107 RNA
copies/ml













a IC, immunocompetent patient infected with GII.4 New Orleans; UNK1, novel, unknown GII.4 norovirus variant 1; UNK2, novel, unknown GII.4 norovirus variant 2.
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virions was extracted using the Qiagen viral RNA kit according to the
manufacturer’s instructions (Valencia, CA).
SISPA reaction. Extracted RNA was reverse transcribed, purified, and
amplified as described elsewhere (39). Briefly, RNA was reverse tran-
scribed with Superscript III (Invitrogen, Carlsbad, CA) using random
hexamers with a unique barcode. Double-stranded DNA was synthesized
by Klenow reaction. The Klenow reaction was used as the template for
random amplification using the unique barcode. The sequence-indepen-
dent single primer amplification (SISPA) reaction mixtures were gel pu-
rified using a QiaQuick gel extraction kit (Qiagen). The purified DNA
samples were submitted to the University of North Carolina high-
throughput sequencing facility for sequencing using Roche 454 Life Sci-
ence FLX Titanium chemistry (454 Life Sciences of Roche, Branford, CT).
Contig assembly. Sequences derived from Roche 454 sequencing were
binned based on the barcode sequence added during the SISPA preparation,
and the barcode sequences were trimmed from the reads in each unique bin,
representing individual samples. Each sample bin was assembled de novo us-
ing CLC Genomics Workbench version 5.1 (CLCBio, Aarhus, Denmark) us-
ing default settings. Consensus sequences were determined for each contig
using the 50% majority rule, and the consensus sequences were used to query
the nonredundant nucleotide database using BLAST within the CLC Genom-
ics Workbench interface. This approach was used to determine the nearest
sequence neighbor for each consensus sequence, which was subsequently
used to conduct a mapping using the closest BLAST match with the reference
sequence. Mapping the trimmed sequences to the reference sequence pro-
vided a framework for identifying putative gaps in the sequencing informa-
tion for each sequence, and the de novo assembly was used to verify the refer-
ence mapping.
Phylogenetic analysis. A total of 10 clones from each specimen for a
total of 50 clones were selected and bidirectionally sequenced for phylo-
genetic analysis. The phylogenetic tree for VP1 of each specimen was built
in PhyML 3.0 (http://www.atgc-montpellier.fr/phyml/versions.php) us-
ing the general time-reversible model (GTR).
Data processing and statistical analysis. The online webserver Galaxy
(http://main.g2.bx.psu.edu/) was used to prepare the Roche 454 data for
analysis. In order to differentiate between process-induced mutations and
native mutations, only sites with a minimum coverage of 30-fold and
minor variants of at least 10% of the total coverage were considered. Using
this criterion, the immunocompetent specimen did not have any variable
sites, indicating that no significant polymorphisms were present. After
excluding minor or spurious mutations, Shannon entropy scores were
generated for each nucleotide position using the Miller-Madow correc-
tion with a log base 2 using R (http://www.r-project.org/) with the pack-
age entropy. Site-by-site variation for each specimen was summarized as
“bits,” with an absolute maximum entropy or variation of 2 bits per nu-
cleotide position if all four nucleotides were equally likely at any site.
Nucleotide entropy scores were grouped by codon triplets, and scores
were added together to obtain an entropy score for each codon position
with a theoretical maximum of 6 bits for codon; thus, entropy is propor-
tional to the number of mutations for each codon position. To determine
positively selected sites in the norovirus population from 1974 to 2014,
full- or near-full-genome (n  541) GII.4 noroviruses were parsed and
analyzed for each gene using the online webserver DataMonkey (http:
//www.datamonkey.org). Potential recombination was assayed using SBP
(single breakpoint) in HyPhy (http://hyphy.org/w/index.php/Main
_Page), and the data were parsed appropriately if a breakpoint was de-
tected. Four methods—SLAC (single likelihood ancestor counting), iFEL
(internal fixed-effect likelihood), FEL (fixed-effect likelihood), and
MEME (mixed-effect model of evolution)—were run on a subset of VP1
to determine the best model (Fig. 1), based on known antigenic sites and
reduction of background noise. The MEME method was determined to be
the best model to identify positively selected sites in the norovirus genome
(40). All P values obtained from DataMonkey MEME analysis were down-
loaded, and each codon position P value was binned into five groups,
depending on the P value (0.001, 0.01, 0.05, 0.1, or 0.1) and
graphed along with the Roche 454 sequencing data in R using the ggplot2
FIG 1 Method for detecting positive selection. Four methods were compared to determine the most appropriate statistical method to determine positive
selection. The VP1 gene was parsed from 240 publicly available GII.4 norovirus sequences (S1) and run using the four available methods SLAC (single-likelihood
ancestor counting), iFEL (internal fixed-effect likelihood), FEL (fixed-effect likelihood), and MEME (mixed-effect model of evolution) in DataMonkey (http:
//www.datamonkey.org). The P values from the four methods (S2) were graphed for comparison. The S, P1, and P2 domains are labeled.
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package. All polymorphisms which met the criteria were graphed, as pre-
viously discussed. To determine clustering of variable and selective sites,
the amino acid absolute distance between all norovirus selective sites (n 
113) and variable sites (n  321) was determined for each gene. The
nearest selective and variable sites, by amino acid distance, were collected
and binned. A proportion test was run on each bin, using R proportion
test, to determine significantly different proportions in each bin. To de-
termine significant clustering in bins, a hypergeometric test to account for
nonreplacement sampling was run using R.
Hypergeometric distribution. The hypergeometric distribution is
similar to a binomial distribution but accounts for sampling in a nonre-
newed population. To accurately determine clustering at each binned site,
once each site is selected it is not reincorporated into the available popu-
lation or is nonrenewed. The hypergeometric distribution for at least X
number of counts is determined as follows:
p(X  x) 
mx   nk  x 
Nk 
where m is the number of all possible sites within a bin, n is nonbinnable
sites, N is the number of all sites, k is the total number of all variable sites,
and x is the number of counts in the bin.
Norovirus simulation. Three norovirus simulations were run to de-
termine the effects of genome size, random proximity of polymorphisms
to selective sites, and number of mutations on norovirus RNA popula-
tions. All simulations were run and results graphed in R. The hypergeo-
metric test was run using the same parameters obtained from the next-
generation sequence data set. The size of the genome or available sites
varied by 5%, 10%, and 40% of the norovirus genome using a uniform
distribution; all the data were combined to achieve a uniform sample size
to obtain the full range of P scores. To obtain the randomization of poly-
morphic and selective sites, a uniform distribution was used to sample the
location of the sites. The number of mutations was obtained from the
next-generation data and selective sites obtained from DataMonkey.
The randomization was repeated 1,000 times, and data from each itera-
tion were collected and graphed. In order to determine the association of
the number of mutations and proximity to positively selected sites, the
model as previously described was run, but instead of randomizing the
location of sites, the number of variable sites was randomized from zero to
all possible sites. The simulation was repeated 1,000 times. Data were
collated as previously described by three possible results— 0 to 2, 3 to 4,
and 4 amino acids from the nearest selected site—and graphed.
Nucleotide sequence accession numbers. All norovirus sequences in
this study are available in GenBank. The UNK1 and UNK2 GII.4 virus
sequences from the three patients are available with the following acces-
sion numbers: KF806495 to KF806534. The GII.4 New Orleans 2009 no-
rovirus from the immunocompetent patient has accession number
JN595867, and the RNA transcript was based on sequence data for acces-
sion number GU134965.
RESULTS
Norovirus viral loads ranged from 106 to 109 genomic copies per
ml. The specimen from the immunocompetent patient had the
highest titer, 2.7  109 genome copies per ml. Patient A, the only
patient with immunodeficiency disease, had the greatest number
of polymorphisms detected (Tables 1 and 2). The other two bone
marrow transplant patients, B and C, with immunosuppression
by drug therapy had norovirus genome copy titers that were 10-
fold lower than and equivalent to, respectively, that of patient A.
There was no association between norovirus genome counts and
number of polymorphisms detected.
Identification of viral RNA populations by Sanger sequenc-
ing. Three patients—patients A, B, and C—tested positive for two
novel GII.4 variants, UNK1 and UNK2, distinct from each other
and not belonging to any known GII.4 virus based on patristic
distance (Fig. 2) or phylogenetic analysis (Fig. 3) (50). Both vari-
ants UNK1 and UNK2 contained deletions in the P2 domain of
the capsid compared to modern noroviruses since GII.4 Farming-
ton Hills 2002. One deletion occurred in aa 391, adjacent to the
external HBGA binding site 2, and the other at aa 298, at a pro-
truding site on the capsid surface (not shown due to 100% dele-
tion in all clones). None of the deletions were present in the GII.4
norovirus variants circulating in 2010. The deletion at aa 298 had
not been previously identified in any GII.4 variant known to date.
The average mutation frequencies of VP1, based on a VP1 of 1,620
nt, obtained from each specimen were 6.6  102, 3.0  102, and
6.2  104 substitution per site in the GII.4 major capsid protein
for specimens A, B, and C, respectively. Specimen A  5, collected 5
months after the first specimen, contained a mixed infection: the
GII.4 variants UNK1 and UNK2 were present in patient A, similar to
the virus in patient C. After separating the two variants, the mutation
frequencies were 1.8  103 and 6.2  104 substitution per site for
each variant in the patient. The mutation frequency for the immuno-
competent specimen could not be determined because it did not con-
tain any nucleotide substitutions among the 10 clones recovered.
Seven of the 50 clones had a premature stop codon at the end of
the S domain. Six out the seven mutants with this deletion were from
the same GII.4 variant, GII.4 UNK2, and were from the same person,
TABLE 2 Norovirus deep-sequencing polymorphisms and MEME sites by gene
Gene




sites by gene size Specimen A Specimen B Specimen C Unique sites
N terminus (NS1-2) 18 0.05 21 7 3 28
VP1 31 0.06 54 22 4 75
P20 (NS4) 11 0.06 30 9 0 38
NTPase (NS3) 15 0.04 28 7 1 36
VPg (NS5) 2 0.02 14 1 0 15
Protease (NS6) 2 0.01 11 2 0 12
Polymerase (NS7) 12 0.02 58 9 5 68
VP2 22 0.08 19 10 2 29
Total 113 NAa 235 67 15 301
a NA, not available.
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with three of the deletion mutants present in the cloning data 5
months afterwards (Fig. 3). The deletion mutants were phylogeneti-
cally distinct from the other clones from the same person (Fig. 3).
The deletions in the S domain led to premature stop codons with the
predicted protein encompassing most of the S domain. Most of the
deletion mutants in patient A were nearly identical to the deletion
mutants found 5 months after the first sample (Fig. 3).
In the cloning data set, most nonsynonymous mutations occurred
in the P2 subdomain, followed by the P1 and S domains. Because
mutations in VP1 were clustered by domain, each domain was ana-
lyzed separately. The nonsynonymous/synonymous (dn/ds) ratios
for the P1 and S domains were less than 1, indicating overall negative
selection. The P2 domain for A, B, and C had dn/ds ratios of 1.7, 1.25,
and 1.15, respectively, indicating the presence of positive selection
pressure in all specimens.
Identification of norovirus polymorphisms in the specimen
population and comparison to circulating viruses. To further
investigate the RNA virus population (quasispecies of each speci-
men), specimens from patients A, B, and C and the IC patient were
analyzed by deep sequencing using Roche 454 sequencing. The
A  5 sample was not processed further because of the presence of
a mixed infection. Genetic polymorphisms from the deep-se-
quencing data were summarized as bit scores as previously de-
scribed. Bit scores for each gene were then overlaid on the P values
obtained from the MEME analysis to identify similar sites between
noroviruses from the immunocompromised patients and circu-
lating noroviruses. In the GII.4 circulating population, a total of
113 positively selected codon sites were identified by MEME anal-
ysis with a P value score of 0.1 (Table 2). All scores from the
MEME analysis that were 0.1 were selected and binned accord-
FIG 2 Patristic and P-distance comparison of novel GII.4 variants. The nucleotide maximum likelihood tree (ML-NT), amino acid maximum likelihood tree (ML-AA),
nucleotide P-distance (P-NT), and amino acid P-distance (P-AA) between GII.4 variants were graphed. The error bars represent 	2 SDs for each group comparison.
UNK1 and UNK2 are described in this study. The other variants and their GenBank accession numbers are GII495.96 (United States, 1995-1996), AY741811; GII4Henry
(Henry, 2001), EU310927; GII4FHills (Farmington Hills, 2002), AY502023; GII4Apeldoorn (Apeldoorn, 2008), HQ009513; GII4NewOrleans (New Orleans, 2009),
GU445325; and GII4Sydney (Sydney, 2012), JX459908. PA, PB, and PC refer to patients A, B, and C, respectively.
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ing to their P values (0.001, 0.01, 0.05, 0.1, or 0.1).
Within this data set, the VP1 gene had the highest number of
positively selected sites, 31, whereas the NS6 and NS5 were the
most conserved, with two positively selected sites each (Table 2).
Adjusting for gene size, VP2 contained the largest number of pos-
itively selected sites, with 8% of the gene under positive selection.
The VP1 and NS4 were equal, at 6% each. The NS7 contained one
of the lowest proportions of selected sites, at 2%.
Regarding the deep-sequencing data, the GII.4-positive speci-
men from the IC patient contained no mutations after filtering
data for low coverage or potentially spurious mutations, but due
to low coverage, only VP1 was analyzed thoroughly (Fig. 4). A
FIG 3 Sanger sequencing analysis. Fifty clones, 10 per specimen, were selected and bidirectionally sequenced. The major capsid protein for all sequences
along with known GII.4 variants was run in PhyML. The sequences of the clones were clustered phylogenetically, and all nucleotide sequences were
translated. All synonymous (blue), nonsynonymous (red), and deleted (gray) codons were summarized graphically. A subset (*) were found to have
premature stop codons. The amino acid positions are noted on the bottom of the graphic. The S domain and P1 and P2 subdomains are labeled
accordingly. GII.4 Farmington Hills 2002 is labeled as F. Hills.
FIG 4 Genome sequence coverage of four GII.4 noroviruses. Four specimens were analyzed by next-generation sequencing. The total number of reads for
specimens A (black), B (blue), and C (red) and the immunocompetent specimen (gold) are shown. The horizontal line is the cutoff below which data were not
included for analysis. Viral protein regions are labeled accordingly.
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FIG 5 Deep-sequencing analysis of norovirus genome. Entropy bit scores at each codon position for each gene are graphed onto the binned P value results for
each codon position from the MEME analysis. All specimens’ genetic polymorphisms, if present, are graphed. Specimens A (black), B (blue), and C (red) are
included. No data from the immunocompetent specimen were available for analysis. The P values were binned according to score: 0.001, 0.01, 0.05, 0.1,
or 0.1. Each virus gene is graphed separately and labeled accordingly. Position summaries for counts, statistical analysis, and results are included as Data Sets
S3 to S6 in the supplemental material. Genome alignments can be provided upon request.
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total of 317 sites throughout the norovirus genome were avail-
able for analysis after discarding minimal or spurious muta-
tions. Of these sites, 301 were unique among the three speci-
mens (Table 2 and Fig. 5). Specimen A contained the highest
number of mutations (235), followed by specimen B (67), and
specimen C (15) (Table 2). The NS5, NS3, and NS6 genes con-
tained the lowest proportions of mutations by gene size, 0.01 to
0.04 (Table 2).
Distribution and magnitude of mutations by gene. To deter-
mine if mutations were randomly distributed across the norovirus
genome, we analyzed the number of mutations per gene using the
hypergeometric test. Only the NS4 gene had a statistically significant
(P0.001) number of mutations (Table 2). The VP1 (P0.22), NS7
(P  0.37), and NS5 (P  0.75) genes did not have significant num-
bers of mutations, whereas the NS1-2 (P  0.03), NS3 (P  0.024),
and NS6 (P  0.002) genes had significantly fewer mutations. To
further investigate VP1, we separated VP1 based on the three recog-
nized domains, S, P1, and P2. P2 had a significantly greater number of
mutations detected (P  0.013), the number of mutations for P1 was
not significant (P  0.502), and the S domain had significantly fewer
mutations (P  0.001).
The VP1 gene had four (1.53, 1.39, 1.29, and 1.16 bits) of the
five (NS4: 1.49 bits) greatest entropy sites on the norovirus ge-
nome corresponding to codon sites 396, 297, 373, and 228, respec-
tively (Fig. 5). The VP2 had one codon site, 140, with an entropy
score over 1 and a bit score of 1.12. The majority of nonstructural
genes, NS1-2, NS4, NS6, and NS7, had at least one site with 1 bit
of entropy. Gene NS1-2 codons with scores of 1 bits were at
positions 204, 239, and 280, NS4 at positions 29, 88, and 174, NS6
at position 35, and NS7 at codons 231, 291, and 365.
Clustering analysis between MEME and entropy sites. To ob-
tain an unbiased estimation of clustering between variable sites
from the norovirus RNA virus population of each patient and the
positively selected sites from the MEME analysis, the difference
between all sites was calculated. Based on previous GII.4 variants,
residue changes occur within 0 to 2 amino acids of positively se-
lected sites (Fig. 6). The minimal difference or nearest site between
any two sites (variable to positively selected and positively selected
to variable) from each gene was binned into a series of amino acid
distance groups (Fig. 7). There was a predominance of sites be-
tween both variable to positively selected and positively selected to
variable within two amino acids of each other (Fig. 7). The num-
ber of variable to selective and selective to variable sites decreased
as the distance between the sites increased. There were signifi-
cantly more positively selected, n  56, sites within 0 to 2 amino
acids of polymorphic sites (P  0.001). Additionally, there were
significantly more variable sites within four amino acids (0 to 2 aa,
n  66, and 3 or 4 aa, n  32) of positively selected MEME sites
(P  0.001) for both groups. All other groups were not significant
(P  0.65). A breakdown by gene indicated that NS3, NS4, VP1,
and VP2 had a variable to selective site distribution similar to that
of the complete norovirus genome (Fig. 7).
In order to obtain a more accurate estimate of significance,
a hypergeometric test was run over the entire norovirus ge-
nome, taking into account mutations by distance, number of
positive selected sites, genome size, and total number of poly-
morphic sites. Although there were proportionally more sites
within 0 to 2 amino acids of each other, the counts were not
significant when accounting for all variables (P  0.836), indi-
cating that clustering was due to random chance and was not
preferential. To further investigate the discrepancy between the
proportion of sites within 0 to 2 amino acids of selective sites
and the results of the hypergeometric test, data were simulated
to identify the effect of genome size where all other variables
remained constant. Genome size data simulation indicated
that the size of the norovirus genome would have to be 30%
smaller (corresponding to 
1,800 aa) in order for the number
of mutations within 0 to 2 amino acids of selective sites to be
significant (Fig. 8A). To verify that a high proportion of muta-
tions would randomly fall within 0 to 2 amino acids of selective
sites given the data obtained from this study, the location of
both selective sites and genetic polymorphisms were random-
ized and binned. The results of the randomized site simulation
were similar to the RNA virus population data from the immu-
FIG 6 Norovirus P2 subdomain polymorphisms for GII.4 noroviruses, 2006 to 2012 major variants. Norovirus GII.4 polymorphisms for 431 noroviruses from
GII.4 2006b (Minerva [gray]), GII.4 2009 (New Orleans), and GII.4 2012 (Sydney) variants were identified. Residues within two codons (yellow) of positively
selected sites (orange) were identified.
Impact of RNA Virus Populations in Virus Evolution
December 2014 Volume 88 Number 24 jvi.asm.org 14191
nocompromised people (Fig. 7 and 8B). The proportions of
polymorphic sites within 0 to 2 amino acids of selective sites
were nearly identical, 0.206 and 0.202 for the immunocompro-
mised patients and simulated data, respectively. To better un-
derstand why the number of polymorphic sites seemed to ran-
domly cluster around selective sites, we ran an additional
simulation, varying only the number of mutations. The results
show that as mutations increase, the residues around the selec-
tive sites become rapidly saturated with genetic polymor-
phisms, and increasing the number of mutations does not pro-
vide an increase in positively selective site changes (Fig. 8C).
Mutations occurring 4 amino acids away from positively se-
lected sites will have little effect and cause neutral or negative
effects on virus viability.
FIG 7 Cluster analysis of variable and positively selected sites. Distance counts for positively selected to nearest genetic polymorphic site (selective to nearest
variable) in the norovirus genome was graphed and labeled accordingly. Distance counts for polymorphic to nearest positively selected (variable to nearest
selective) sites in the norovirus genome and for each gene were graphed and labeled accordingly.
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DISCUSSION
GII.4 is the most common genotype associated with norovirus
gastroenteritis outbreaks. The GII.4 viruses found in immuno-
compromised patients described here not only are novel but also
are more closely related to GII.4 variants which currently do not
circulate. The presence of these variants indicates that there may
be a much larger pool of GII.4 noroviruses circulating in human
populations than is captured by routine outbreak surveillance.
These patients may serve as reservoirs of novel norovirus variants
based on the random nature of mutations and the patients’ lack of
a fully functioning immune system. These results also show that
the sequence space available for evolution of norovirus is strongly
suppressed by the immune system. Only patient A, with primary
immunodeficiency disease, had large numbers of polymorphisms.
In addition, the high degree of genetic variability found in the NS4
gene, the only gene which had a significantly enriched number of
genetic polymorphisms, indicates an important yet unknown role
for this gene in norovirus pathogenesis.
The identification of these viruses in bone marrow transplant
patients made it possible to assess the genetic diversity of an active
infection in vivo. All three patients were undergoing immunosup-
pression to various degrees with drug regimens aimed at prevent-
ing graft rejection. The immunosuppressant drugs were broadly
acting, such as corticosteroids, IL-2 competitors, and tumor
necrosis factor alpha (TNF-) binders, but there were also specific
drugs which depleted T cells (Table 1). Using deep sequencing
along with bioinformatic analysis, we were able combine data
from an ongoing infection and analyze them in terms of noro-
virus evolution. Because human noroviruses are noncultur-
able, many of the norovirus gene products and their functions
are unknown. Many of the variable sites in the RNA virus pop-
ulation of the three patients were within 0 to 2 amino acids of
FIG 8 Norovirus data simulation. Data obtained from deep sequencing of immunocompromised patients were used to simulate the effects of several variables.
(A) The effect of genome size on hypergeometric scores of the norovirus data were simulated, ranging from 1,500 to 3,500 amino acids. The norovirus genome
size is indicated by the vertical line. (B) The random clustering between genetic polymorphisms and positively selected sites was investigated. The distance from
the positively selected to nearest variable site was simulated 1,000 times, each randomly distributed and binned according to distance. (C) The number of
mutations and its effect on random localization near positively selected site are shown. The number of variable sites was varied from zero to all sites, and the
distance between a genetic polymorphism and the nearest positively selected site was obtained and binned based on three possible outcomes: amino acid distance
of 0 to 2 (black), 3 or 4 (blue), and 4 (red).
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the 113 positively selected sites. This result would argue that
RNA virus populations in immunocompromised patients are
mutating in a manner similar to that of circulating noroviruses.
More thorough analysis argues, however, that this is not true
and that mutations are occurring randomly. These divergent
results from the same data set highlight norovirus evolutionary
benefits and limitations.
We showed that the high number of mutations within 0 to 2
amino acids of positively selective sites is a result of the balance
between genome size and the number of positively selected
sites. The positively selective sites encompass 535 residues
within 0 to 2 amino acids of the 113 identified in this study.
Norovirus has 
2,507 total residues in the entire genome,
which means that 21% of the norovirus genome, or greater
than 1 of 5 mutations, would have a positive effect on norovirus
in the occurrence of a random mutation. Previous studies have
shown that immunocompromised patients infected with noro-
virus shed antigenically distinct viruses over time (32). Taken
together, this study and that of Debbink et al. (32) show that
immunocompromised people can shed antigenically distinct
viruses and that antigenic changes occur randomly. If either the
number of selected sites or genome size is different, it would
change the balance between positive and negative selection,
with potentially detrimental effects for the virus. The number
of mutations in vivo is balanced against the negative effect of
mutations. Although we may not have identified all possible
mutations, data simulation shows that an increase in the num-
ber of mutations may not be tolerated due to the increased risk
of negative selection. To our knowledge, this is the first time
this has been determined for norovirus.
The location of polymorphic sites was determined to be ran-
dom across the genome, and the number of mutations per gene
was not significant except in the case of the NS4 gene. The NS4
gene, P18, P20, and P22 in GV, GII, and GI noroviruses, respec-
tively, has been shown to be the most variable gene of the non-
structural proteins (22, 41). Interestingly, the function of NS4 has
not been identified, and it is unclear why this protein is highly
variable. Two published studies, one involving human Norwalk
virus (GI.1) and the other with murine noroviruses (MNV), indi-
cate that NS4 proteins may not have the same function (42, 43).
The NS4 in GI.1 has an endoplasmic reticulum (ER) export signal
and is involved in Golgi disassembly, whereas MNV has no effect
on the Golgi and lacks the ER export signal (42, 43). The signifi-
cance of this difference is currently unknown. The presence of a
membrane-associated domain (42) suggests that NS4 is involved
in the replication complex and may associate with VP1. The clus-
tering of mutations within this gene makes the NS4 a potentially
important target for future research.
The VP1 gene is the best-studied norovirus gene. VP1 contains
the antigenic determinants for norovirus and evolves in response
to host population immunity. We did not find any increase in the
number of polymorphic sites in VP1 or an increase in number of
sites within 0 to 2 amino acids of positively selected sites. Never-
theless, the magnitudes of mutations are noteworthy. Of the five
largest entropy bit scores (1.16 to 1.53), four occur in VP1, indi-
cating that there is high turnover at the same sites. Sites 297, 373,
and 396 are all known to affect antigenic or HBGA binding (44–
46). Site 228 is not located in an antigenic or HBGA binding site
but is predicted to be buried in the hinge region. Buried and non-
contiguous residues have been previously determined to have
conformational effects on the norovirus VLP and consequently
antibody binding (47). Additionally, Lindesmith et al. (47) also
showed through mutagenesis and surrogate neutralization assays
that not only are the surface epitopes of importance but so are the
buried sites which may alter the conformational surface and
change the neutralization capacity of antibodies. Further studies
are needed to characterize the hinge region as a possible site af-
fecting immune evasion.
We showed that norovirus-infected immunocompromised
patients can be potential reservoirs for novel norovirus strains by
the presence of two novel GII.4 variant viruses, one of which in-
fected another immunocompromised person. Our comparison of
an immunodeficient norovirus RNA population with positively
selective sites allowed us to further determine that mutations in
such populations are random, and only the NS4 gene has a signif-
icant number of mutations. Although most mutations occurred
within 0 to 2 amino acids of selective sites, this was a function of
genome size and the number of selective sites and not specific
clustering. Because immunocompromised patients are often hos-
pitalized for long periods, there is a significant risk of direct or
indirect contact with other susceptible patients, and it is impera-
tive that strict hygiene practices be used to prevent further spread
of these viruses (48). While a norovirus vaccine may not be effec-
tive for these patients, the potential use of antiviral compounds
which are under development may assist in treating and prevent-
ing norovirus infections in the immunocompromised population
(49).
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